DAB2IP and prostate carcinoma: Overall, our experiments confirmed that Thio counteracts the aggressiveness of prostate cancer cells in vitro, but also revealed that the Thio effect is less efficient in the absence of DAB2IP, providing the first experimental evidence that DAB2IP upregulation can contribute to the anti-tumor action of this drug.